Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
- Status
- recruiting
- Phase
- Phase 2
- Institution
- Charles S. Grob, M.D.
- Principal investigator
- Charles S. Grob, M.D.
- Start date
- 2025-01-19
- End date
- 2027-12-31
- Registry ID
- NCT05403086
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.